As the world economy suffers from an unprecedented sanitary crisis, the outlook is blurred for the vibrant though fragile European biotech ecosystem. Can life-science investors support innovators financing needs from seed to A/B rounds? What to expect from stock-exchange in Europe and US? Will big pharma take the risk of partnership and M&A in the current environment? How big is the place of biotech in a post-COVID-19 world?
Speakers
CEO at Sensorion
Nawal has served as CEO since 2017. She started out at Baxter, where she was strategy and operational excellence manager, quality operations director and senior director strategy before becoming Vice President of the bioSimilars business unit. In 2014, she became Vice President of the Global Hemophilia Franchise at Baxalta. In 2016, she headed up the global genetic diseases franchise at Shire, where she supervised all marketing, business and strategy aspects of this global division’s product portfolio.
Associate and Patient at Andera Partners
Raphaël joined Andera Partners in 2001. He began his career in London where he worked for 7 years, first in the private clinic group Générale de Santé and then in investment banking at Salomon Smith Barney and Goldman Sachs, advising companies in the healthcare sector. Raphaël has made numerous investments and exits in the last 20 years at Andera. He currently sits on the boards of AM Pharma, Grey Wolf, Enyo Pharma, MedDay, ReViral and Exciva. Raphaël is a graduate of HEC and holds a DEA in Applied Economics from IEP Paris.
Co-founder and chairman at Ysiopa (ex-LNC Therapeutics) and Treefrogs
Pharm.D and graduate from ESCEM Management School and ESSEC, Jean-Luc Treillou is a biotech serial-entrepreneur. He started out in the pharmaceutical industry at GSK and Sanofi before joining Oenobiol as deputy executive director. In 2008, he created SOPI Conseil and served as general manager at Nutrionix from 2009 to 2011. He co-founded Ysiopa Biosciences in 2011 and Treefrogs in 2018 where he currently serves as chairman of the board.
Board Member of Angels Santé/Angels for Health
A seasoned Business Angel, Alain PUJOL is having invested in 15 startups. Alain spent more than 20 years in international business positions in large pharmaceutical companies (Sanofi and Aventis), in a biotech startup (CEO of Digestar) and in a specialty devices & pharmaceutical startup (VP Europe INO Therapeutics). Alain is also the founder of APHC Consulting, specialized in open innovation. His expertise is in many therapeutic fields including Anti-infectives, CV, Diabetes and Oncology. Angels Santé/Angels for Health is the largest Business Angels Network in Europe investing in healthcare companies.Relive the event
Last events
Event
Bioconvergence – The New Investment era in Health in Neighborhood
Neighborhood is proud to Host ENV, a new Pan-European Venture Fund specializing in Healthtech. We are thrilled to host an…
Event
Afterwork: Key Takeaways from JP Morgan’s Annual Healthcare Conference 2024 in Neighborhood
After two years of turmoil, tough financing, pipeline slimming and cost-cutting… prospects finally look brighter for the…
Event
The Neighborhood Showcase 2023 in Neighborhood
After a year of hard work on producing their development plans and regulatory strategy, Neighborhood’s Start-up Class of 2023 will…
Event
Afterwork: AI a revolution for Healthtech development and Investment? in Neighborhood
AI and in silico models are set to revolutionize biotech investments and transform the entire health innovation ecosystem, join us…
We'd love to get to know you
Join us, we offer you an extraordinary chance to learn, to develop and to be part of an exciting experience and team.
Tell us your story